Literature DB >> 2815227

Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism.

T Tomson1, J O Svensson, P Hilton-Brown.   

Abstract

The effect of a dose change on the plasma concentration of carbamazepine (CBZ) was studied in 13 epileptic patients, all with a CBZ dose of at least 800 mg/day. A disproportionately small rise in the plasma concentration of CBZ was found in 10 of the patients. The ratio between the final metabolite 10,11-dihydro-10,11-trans-dihydroxy-CBZ and CBZ in plasma was higher after dose increase in the 10 patients with a small rise in CBZ levels, indicating a dose-dependent autoinduction of CBZ metabolism. The ratio between the active intermediary metabolite, CBZ-epoxide, and CBZ was unaltered by the dose change in all patients. This indicates that CBZ plasma level determinations can be used for prediction of the total effect of CBZ treatment during high as well as low dosage.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2815227

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.

Authors:  K Wilbur; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Anti-epileptic drugs and hormonal treatments.

Authors:  Clare A Johnston; Pamela M Crawford
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

3.  Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.

Authors:  D M Reith; W D Hooper; J Parke; B Charles
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

Review 4.  Interactions between antiepileptic drugs and hormonal contraception.

Authors:  Pamela Crawford
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.

Authors:  U Bronner; L L Gustafsson; F Doua; O Ericsson; T Miézan; M Rais; L Rombo
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

8.  Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.

Authors:  Katarina Wide; Hanna Larsson; Leif Bertilsson; Ulf Diczfalusy
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

9.  Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects.

Authors:  G Kennebäck; L Bergfeldt; T Tomson
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.